Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study

BACKGROUND: N8‐GP (turoctocog alfa pegol; Esperoct) is a glycoPEGylated human recombinant factor VIII (FVIII). OBJECTIVES: Pathfinder8 (NCT01480180) was a phase 3, multinational, open‐label, nonrandomized trial to investigate the long‐term safety and efficacy of N8‐GP in people of all ages with seve...

Descripción completa

Detalles Bibliográficos
Autores principales: Lentz, Steven R., Kavakli, Kaan, Klamroth, Robert, Misgav, Mudi, Nagao, Azusa, Tosetto, Alberto, Jørgensen, Pernille Juul, Zak, Marek, Nemes, Laszlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918113/
https://www.ncbi.nlm.nih.gov/pubmed/35308099
http://dx.doi.org/10.1002/rth2.12674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918113/
https://www.ncbi.nlm.nih.gov/pubmed/35308099
http://dx.doi.org/10.1002/rth2.12674

Ejemplares similares